Showing results (31-40 of 49) with videos related to
Sort By:
Pageof 5
The Journal of Biological Chemistry|August 4, 2022
Induction of zinc finger protein RNF6 auto-ubiquitination for the treatment of myeloma and chronic myeloid leukemiaHaixia Zhuang, Ying Ren, Chenyu Mao, et al.Frontiers in Oncology|July 9, 2020
Prognostic Value of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Combined Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Stage IV Advanced Gastric CancerHuan Wang, Yongfeng Ding, Ning Li, et al.Current Oncology (Toronto, Ont.)|November 24, 2022
Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with ChemotherapyXiaolu Ma, Yongfeng Ding, Jiong Qian, et al.Cancer Medicine|October 3, 2023
The Memorial Sloan Kettering Prognostic Score: Correlation with survival in patients with advanced gastric cancerMingyu Wan, Yongfeng Ding, Xiaolu Ma, et al.Frontiers in Oncology|November 17, 2022
Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatmentMingyu Wan, Yongfeng Ding, Chenyu Mao, et al.Cancer Chemotherapy and Pharmacology|May 28, 2015
A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancerHaiping Jiang, Jiong Qian, Peng Zhao, et al.Translational Cancer Research|January 16, 2025
Safety and efficacy of mecapegfilgrastim in preventing neutropenia in patients with head and neck cancer: a multicenter, prospective, observational, real-world studyGang Cheng, Yong Chen, Nong Xu, et al.Journal of Hematology & Oncology|December 31, 2024
Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib studyChenyu Mao, Anwen Xiong, Jiong Qian, et al.BMC Cancer|August 16, 2020
Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trialHaiping Jiang, Yulong Zheng, Jiong Qian, et al.Cancer Immunology, Immunotherapy : CII|October 18, 2020
Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b studyHaiping Jiang, Yulong Zheng, Jiong Qian, et al.Pageof 5